15) In the absence of contraindications, NSAIDs constitute the first-line pharmacological
treatment of symptomatic spondyloarthritis (A) (10). 22) TNFα antagonist therapy should be offered to patients with persistent disease activity despite conventional treatment, according to Doxorubicin ic50 the recommendations shown in Fig. 1 (D) (9,8). Fig. 1. Indications for TNFα antagonist therapy. 28) Total arthroplasty can be offered to patients of any age who have structural joint damage responsible for refractory pain and severe functional impairments (D) (10). Several unresolved issues regarding the management of patients with spondyloarthritis were identified by the task force: • definition and criteria of remission
in spondyloarthritis (depending on the phenotypic form); These practice guidelines will now be disseminated. In 2 years (2016), the task force plans to evaluate their impact and to decide, based on the availability of new data, on a revision date. D.W. conducts occasional interventions for AbbVie, BMS, MSD, Pfizer, Roche Chugai, Amgen, Nordic Pharma, UCB, SOBI, andet Sanofi Aventis and reports indirect interests in Abbvie, Pfizer, Roche Chugai, Servier, and MSD. C.L. conducts occasional interventions for Abbvie, BMS, MSD, Pfizer, Roche-Chugai, and UCB. P.C. conducts occasional interventions for Abbvie, BMS, Janssen, MSD, Pfizer, Roche-Chugai, and UCB and reports indirect interests (including P-type ATPase grants or donations to SRT1720 ic50 an organization) in Pfizer and Roche-Chugai. P.G. conducts occasional interventions for Abbvie, BMS, Janssen, Lilly,
MSD, Pfizer, Roche-Chugai, and UCB and reports indirect interests (including grants or donations to an organization) in Abbvie, BMS, Janssen, Lilly, MSD, Pfizer, Roche-Chugai, and UCB. B.C. reports long-lasting or permanent ties with MSD, Pfizer, Roche-Chugai, and UCB; as well as indirect interests (including grants or donations to an organization) in Pfizer and Roche-Chugai. He also conducts occasional interventions for Abbvie, BMS, Cellegen, Lilly, Nordic, Novartis, and Vertex. F.G. conducts occasional interventions for GSK (scientific committee) and Pfizer (symposiums) and receives grants from Expansciences, Merck, and Sanofi. C.H. conducts occasional interventions for Abbvie, Pfizer, Roche, UCB, MSD, and BMS. He also receives grants from Expansciences, Merck, and Sanofi. C.M. conducts occasional interventions for Abbvie, BMS, Janssen, MSD, Pfizer, Roche-Chugai, and UCB and reports indirect interests in Abbvie, Pfizer, Roche-Chugai, and UCB. M.D. receives honoraria paid to him personally for work as a consultant or speaker in the field of spondyloarthritis during satellite symposia organized by Pfizer, Abbvie, UCB, Eli-Lilly, Sanofi-Aventis, Roche, and Novartis.